股票代码：002750 股票简称：*ST 龙津 公告编号：2025-034 昆明龙津药业股份有限公司 第六届监事会第六次会议决议公告 经审核，监事会认为董事会编制和审核公司 2024 年年度报告的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案详见公司披露的《2024 年年度报告》摘要（公告编号：2025-032）、 《2024 年年度报告》全文（公告编号：2025-033），本议案需提交股东会审议。 （二）会议以 3 票同意，0 票反对，0 票弃权，审议通过了关于 2024 年度监 事会工作报告的议案。 本议案详见公司披露的《2024 年度监事会工作报告》（公告编号：2025-039）， 本议案需提交股东会审议。 1 （三）会议以 3 票同意，0 票反对，0 票弃权，审议通过了关于 2024 年度利 润分配预案的议案。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 昆明龙津药业股份有限公司（以下简称"公司"）第六届监事会第六次会议 于 ...

股票代码：002750 股票简称：*ST 龙津 公告编号：2025-031 （二）会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于 2024 年度 董事会工作报告的议案》。 2024 年度董事会工作报告详见公司 2024 年年度报告相关章节，本议案需提 交股东会审议。 一、董事会会议召开情况 昆明龙津药业股份有限公司（以下简称"公司"）第六届董事会第八次会议 于 2025 年 4 月 14 日以电子邮件、书面通知、专人送达等方式发出会议通知及会 议资料。本次会议由董事长樊献俄先生召集并主持，于 2025 年 4 月 24 日以现场 会议结合通讯表决的方式在公司会议室召开，应参与表决董事 9 名，截至会议通 知要求的表决截止时间，实际参与表决董事 9 名，其中周晓南、魏利军采用通讯 表决方式参会表决。公司监事会成员、总经理列席会议。会议的召集、召开符合 《中华人民共和国公司法》和《公司章程》等有关规定。 二、董事会会议审议情况 （一）会议以 9 票同意，0 票反对，0 票弃权，审议通过了《关于 2024 年年 度报告全文及摘要的议案》。 全体董事、监事及高级管理人员已签署书面意见，董事会审议通过《2 ...

股票代码：002750 股票简称：*ST 龙津 公告编号：2025-035 昆明龙津药业股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、审议程序 昆明龙津药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 了第六届董事会第八次会议，会议以 9 票同意，0 票反对，0 票弃权，审议通过 了《关于 2024 年度利润分配预案的议案》，本议案尚需提交公司 2024 年年度股 东会审议。 二、利润分配和资本公积金转增股本方案的基本情况 （一）本次利润分配和资本公积金转增股本方案的基本内容 1、分配基准：2024 年度 2、经中审众环会计师事务所（特殊普通合伙）审计，2024 年度公司实现归 属于母公司股东的净利润为-41,443,575.30 元，因公司亏损，本报告期公司未提 取盈余公积和任意公积；截至 2024 年末，母公司累计未分配利润为 43,499,820.98 元，合并报表累计未分配利润为 18,950,761.77 元，公司总股本为 400,500,000 元。 3、公司 ...

股票代码：002750 股票简称：*ST 龙津 公告编号：2025-044 昆明龙津药业股份有限公司 关于公司股票停牌暨可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 昆明龙津药业股份有限公司（以下简称"公司"）2024 年年度报告披露后 存在终止上市情形，因公司 2024 年度经审计的利润总额、净利润、扣除非经常 性损益后的净利润三者均为负值，且扣除后的营业收入低于 3 亿元。根据《深圳 证券交易所股票上市规则（2024 年修订）》（以下简称"股票上市规则"）第 9.3.12 条第一项规定的情形，公司股票将被深圳证券交易所终止上市。 根据《股票上市规则》9.3.13 条的规定：上市公司出现本规则第 9.3.12 条第 一项至第六项情形的，应当在披露年度报告的同时披露公司股票可能被终止上市 的风险提示公告。公司股票于 2025 年 4 月 25 日起停牌。 公司郑重提醒广大投资者，《证券时报》和深圳证券交易所网站 1 （www.szse.cn）为公司选定的信息披露媒体，公司所有信息均以在上述媒体披 露的信息为准。请广大 ...

Financial Performance - The basic earnings per share for 2024 is -0.1035 yuan, showing a 41.56% improvement compared to -0.1771 yuan in 2023 [1] - The net profit for 2024 is -0.41 billion yuan, which is a 42.25% increase from -0.71 billion yuan in 2023 [1] - The operating revenue for 2024 is 0.66 billion yuan, reflecting a decrease of 24.14% from 0.87 billion yuan in 2023 [1] - The return on equity for 2024 is -8.44%, an improvement of 34.88% from -12.96% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 23,725.74 million shares, accounting for 59.51% of the circulating shares, with a change of 343.80 million shares from the previous period [1] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 15,778.23 million shares, representing 39.57% of the total share capital, with no change [2] - New entrants among the top shareholders include Xu Jiawei with 333.02 million shares and Wang Qiyu with 251.00 million shares [2] Dividend Distribution - No specific dividend distribution plan is mentioned in the provided data [3]

Financial Performance - The company reported a negative total profit, net profit, and net profit after deducting non-recurring gains and losses for the fiscal year 2024, which may lead to delisting from the Shenzhen Stock Exchange [4]. - The company's audited operating revenue for the fiscal year 2024 is below 300 million RMB, which is a critical threshold for maintaining its listing status [4]. - The company's operating revenue for 2024 was ¥66,479,185.17, a decrease of 23.25% compared to ¥86,622,523.39 in 2023 [6]. - The net profit attributable to shareholders for 2024 was -¥41,443,575.30, an improvement of 41.58% from -¥70,941,451.11 in 2023 [6]. - The total revenue for 2024 was ¥66,479,185.17, a decrease of 23.25% compared to ¥86,622,523.39 in 2023 [44]. - The pharmaceutical manufacturing sector generated ¥48,309,868.71, accounting for 72.67% of total revenue, down 35.15% from the previous year [44]. - The planting industry saw a significant increase in revenue to ¥13,724,716.18, representing a 207.00% growth from ¥4,470,573.66 in 2023 [44]. Cash Flow and Investments - The net cash flow from operating activities for 2024 was -¥34,236,642.36, showing a 12.80% improvement from -¥39,260,741.79 in 2023 [6]. - The company’s investment activities generated a net cash flow of ¥84,878,649.07 in 2024, an increase of 51.46% from ¥56,040,440.79 in 2023 [59]. - The company has invested a total of 28,196,000 RMB in entrusted financial management, with 5,313,000 RMB in outstanding balances [171]. Assets and Liabilities - The total assets at the end of 2024 were ¥574,398,586.84, a decrease of 9.06% from ¥631,634,251.67 at the end of 2023 [6]. - The total liabilities decreased from ¥90,507,766.87 to ¥80,185,043.61, a reduction of approximately 11.6% [199]. - Total current assets decreased from ¥384,056,293.30 to ¥338,177,284.73, a decline of approximately 11.97% [197]. - Total non-current assets decreased from ¥247,577,958.37 to ¥236,221,302.11, a decline of about 4.9% [198]. - The company reported a significant increase in cash reserves, indicating improved liquidity position [197]. Research and Development - The company’s R&D investment accounted for 20% of sales revenue, with over 20% of employees dedicated to R&D efforts [40]. - The company has undertaken two major national drug creation projects and one key national research project, enhancing its innovation capabilities [40]. - The company is actively engaged in the research and development of high-end chemical generics and innovative drugs, particularly in the cardiovascular and metabolic categories, to expand its product line and enhance its competitive advantage [82]. Market and Product Strategy - The company is focused on enhancing its core competitiveness through the development of its pharmaceutical manufacturing business and the establishment of technical R&D platforms [37]. - The company aims to expand its market presence by adjusting its sales structure and enhancing its marketing strategies across various channels, including collaborations with mainstream commercial partners [77]. - The company is facing increased revenue pressure due to price reductions in its core product, with a new marketing strategy aimed at stabilizing sales and promoting recently launched products [76]. Governance and Management - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations, and maintains effective communication with investors [91]. - The company operates independently from its controlling shareholders in terms of business, personnel, assets, and finances, ensuring no conflicts of interest or unfair transactions [93]. - The company has a complete and independent financial management system, with no interference from controlling shareholders in its financial decisions [94]. Environmental and Social Responsibility - The company emphasizes safety and environmental protection in its production processes, having established safety management systems and undergone safety standard certification, but acknowledges the potential for accidents and regulatory challenges [84]. - The company actively engages in social responsibility initiatives, including educational funds and donations to support rural revitalization efforts [135]. - The company has achieved a reduction in pollutant emissions during production, adhering to approved discharge limits and monitoring environmental impact [135]. Risks and Challenges - The company faces risks from regulatory changes in the pharmaceutical industry, which could adversely affect sales and overall performance, particularly for its core product, the injection of Ligusticum Chuanxiong [80]. - The company is at risk of reduced non-core income due to a single product structure and high R&D costs, which could significantly impact its net profit if cash management returns decline or government subsidies decrease [85]. - The company may face asset impairment risks if the performance of acquired assets or capitalized R&D expenditures does not meet expectations, potentially affecting its financial results [86]. Shareholder Engagement - The total number of ordinary shareholders at the end of the reporting period was 30,822, compared to 29,091 at the end of the previous month, indicating an increase in shareholder engagement [180]. - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 39.40% of the shares, totaling 157,782,293 ordinary shares [181]. - The company has not experienced any changes in its controlling shareholder during the reporting period [182]. Audit and Compliance - The audit opinion issued for Longjin Pharmaceutical's financial statements was a standard unqualified opinion, reflecting fair presentation according to accounting standards [190]. - The audit report emphasizes the importance of internal controls in preventing material misstatements due to fraud or error [194]. - The internal control audit report was issued with a standard unqualified opinion, consistent with the board's self-evaluation [129].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、昆明龙津药业股份有限公司（以下简称"公司"）股票 2025 年 4 月 21 日收盘价为 1.24 元/股，总市值为 4.97 亿元，低于 5 亿元。根据《深圳证券交易 所股票上市规则（2024 年修订）》（以下简称"股票上市规则"）第 9.2.1 条第 一款第（六）项的规定，若公司股票连续二十个交易日收盘总市值均低于 5 亿元， 公司股票将被深圳证券交易所终止上市交易。 2、根据《股票上市规则》第 9.2.3 条规定，上市公司首次出现股票收盘总市 值低于 5 亿元的，应当在次一交易日开市前披露公司股票可能被终止上市的风险 提示公告。 股票代码：002750 股票简称：*ST 龙津 公告编号：2025-030 昆明龙津药业股份有限公司 关于公司股票可能被终止上市的风险提示公告 公司郑重提醒广大投资者，《证券时报》和深圳证券交易所网站 （www.szse.cn）为公司选定的信息披露媒体，公司所有信息均以在上述媒体披 露的信息为准。请广大投资者理性投资，注意风险。 三、历次终止上市风险提示公告的披露情 ...

Group 1 - *ST Jiayao (300108.SZ) has closed below 1 yuan for 12 consecutive trading days, and if it remains below 1 yuan for 20 consecutive trading days, it will face delisting [1] - *ST Longjin (002750.SZ) closed at 1.24 yuan per share on April 11, 2025, with a total market value of 497 million yuan; if the total market value remains below 500 million yuan for 20 consecutive trading days, it will face delisting [1] - *ST Aonong (603363.SH) has a negative net asset for 2023 and continuous losses, resulting in a delisting risk warning; if it does not meet the conditions to lift the warning in 2024, it will face delisting [1] Group 2 - *ST Pengbo (600804.SH) received an audit report with a disclaimer of opinion for 2023, leading to a delisting risk warning; if the 2024 financial report also receives a qualified or adverse opinion, it will face delisting [1] - *ST Dongyuan (002310.SZ) has a negative net asset for 2023 and continuous losses, resulting in a delisting risk warning; if the 2024 financial report triggers delisting conditions, it will face delisting [1] - *ST Gongzhi (000584.SZ) received an audit report with a disclaimer of opinion and a denied internal control report for 2023, leading to a delisting risk warning; if the 2024 financial or internal control report triggers delisting conditions, it will face delisting [2] Group 3 - *ST Xinning (300013.SZ) has a negative net asset for 2023, resulting in a delisting risk warning; if the 2024 financial report triggers delisting conditions, it will face delisting [2]

股票代码：002750 股票简称：*ST 龙津 公告编号：2025-029 昆明龙津药业股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、昆明龙津药业股份有限公司（以下简称"公司"）股票 2025 年 4 月 11 日收盘价为 1.24 元/股，总市值为 4.97 亿元，低于 5 亿元。根据《深圳证券交易 所股票上市规则（2024 年修订）》（以下简称"股票上市规则"）第 9.2.1 条第 一款第（六）项的规定，若公司股票连续二十个交易日收盘总市值均低于 5 亿元， 公司股票将被深圳证券交易所终止上市交易。 2、根据《股票上市规则》第 9.2.3 条规定，上市公司首次出现股票收盘总市 值低于 5 亿元的，应当在次一交易日开市前披露公司股票可能被终止上市的风险 提示公告。 3、公司于 2024 年 4 月 30 日披露《关于公司股票交易被实行退市风险警示 暨停牌的公告》（公告编号：2024-040），公司股票于 2024 年 5 月 6 日开市起 被实施退市风险警示。公司于 2025 年 1 ...

股票代码：002750 股票简称：*ST 龙津 公告编号：2025-028 昆明龙津药业股份有限公司 关于 2024 年年度报告编制及审计进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 根据《深圳证券交易所股票上市规则（2024 年修订）》（以下简称"股票 上市规则"）、《深圳证券交易所上市公司自律监管指南第 1 号——业务办理（2024 年修订）》的有关规定，财务类退市风险公司应当分别在年度报告预约披露日前 二十个交易日和十个交易日，披露年度报告编制及最新审计进展情况，说明是否 存在可能导致财务会计报告或者财务报告内部控制被出具非无保留意见的事项 及具体情况；在重大会计处理、关键审计事项、审计意见类型、审计报告出具时 间安排等事项上是否与会计师事务所存在重大分歧。 经昆明龙津药业股份有限公司（以下简称"公司"）与中审众环会计师事务 所（特殊普通合伙）（以下简称"会计师事务所"）交流沟通，现将公司 2024 年年度报告编制及最新审计进展情况公告如下： 一、2024 年年度报告编制及最新审计进展情况 截止本公告披露日，公司正有序推进 20 ...